more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$5.54 USD

+0.02 (0.36%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.55 +0.01 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

by Zacks Equity Research Published on May 27,2020

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Here's How Americans Are Regaining Confidence: 5 Picks

by Sanghamitra Saha Published on May 27,2020

U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

Tap the Solid Momentum in These 5 Solid High-Beta Stocks

by Sanghamitra Saha Published on May 26,2020

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

earnings

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

by Sanghamitra Saha Published on May 26,2020

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Coronavirus Makes Biotech ETFs Red Hot

by Sweta Killa Published on April 21,2020

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review

by Zacks Equity Research Published on April 17,2020

The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.

biotechs

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

by Zacks Equity Research Published on March 26,2020

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

by Zacks Equity Research Published on March 26,2020

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

medical

Novavax Rallies as Influenza Vaccine Meets All Goals in Study

by Zacks Equity Research Published on March 25,2020

Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

by Daniel Laboe Published on March 25,2020

It is only a matter of time before this virus anxiety is a thing of the past.

Coronavirus Drug Development Race to Boost These 4 Stocks

by Zacks Equity Research Published on March 25,2020

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Aytu BioScience to Issue Coronavirus Rapid Test in North America

by Zacks Equity Research Published on March 24,2020

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

biotechs

Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine

by Zacks Equity Research Published on March 24,2020

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.

Axsome Expedites Completion Timeline of AD Study on AXS-05

by Zacks Equity Research Published on March 23,2020

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

biotechs

Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group

by Zacks Equity Research Published on March 20,2020

The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

biotechs

IMV to Develop Vaccine Candidate Against COVID-19, Shares Up

by Zacks Equity Research Published on March 19,2020

IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.

medical

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson Published on March 17,2020

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts

by Zacks Equity Research Published on March 16,2020

Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.

biotechs

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

by Kaibalya Pravo Dey Published on March 16,2020

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Inovio (INO) Posts Wider Q4 Loss, Gets COVID-19 Vaccine Grant

by Zacks Equity Research Published on March 13,2020

Inovio's (INO) loss in the fourth quarter falls shy of estimates and revenues too miss the mark. The company is focused on developing INO-4800, its DNA vaccine, against COVID-19.

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

by Kinjel Shah Published on March 13,2020

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri Published on March 13,2020

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.